Financial Performance - Aptose reported a net loss of $51.2 million for the year ended December 31, 2023, an increase of $9.4 million compared to a net loss of $41.8 million in 2022[12]. - Cash and cash equivalents decreased to $9.3 million as of December 31, 2023, down from $47.0 million at the end of 2022[10]. - Total shareholders' equity decreased to $(2.9) million as of December 31, 2023, compared to $37.7 million in 2022[10]. Research and Development - Research and development expenses rose to $36.8 million in 2023, up $8.7 million from $28.1 million in 2022, primarily due to increased costs associated with the tuspetinib program[14]. - Tuspetinib achieved a complete response/complete response with partial hematologic recovery (CR/CRh) rate of 36% among patients naive to venetoclax at the recommended Phase 2 dose of 80 mg[5]. - The G3 formulation of luxeptinib demonstrated approximately 10-fold better absorption compared to the original G1 formulation, achieving desired plasma exposure levels[7]. - The company plans to initiate a pilot triplet study of tuspetinib, venetoclax, and a hypomethylating agent in frontline therapy for newly diagnosed AML patients in Summer 2024[8]. Capital and Funding - The company completed a public offering on January 30, 2024, raising approximately $9.7 million from the sale of 5,649,122 common shares at $1.71 per share[3]. - A private placement with Hanmi Pharmaceutical on January 31, 2024, generated $4 million, with shares sold at $1.90 each, an 11% premium over the public offering price[4]. Risks and Uncertainties - The company acknowledges significant risks and uncertainties that could impact future results, including capital acquisition for research and operations[23]. - Early-stage drug development risks include demonstrating efficacy, development time/cost, and regulatory approval processes[23]. - There is a potential risk of new manufacturers failing to produce acceptable GMP batches in sufficient quantities[23]. - Unexpected manufacturing defects are highlighted as a significant risk factor[23]. - The company does not intend to update forward-looking statements unless required by law, indicating a cautious approach to investor communications[24]. - Investors are advised not to overly rely on forward-looking statements due to inherent uncertainties[24]. Administrative Expenses - General and administrative expenses increased to $15.6 million in 2023, up from $14.5 million in 2022, driven by higher salaries and professional fees[17].

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:li ...

Core Viewpoint - Aptose Biosciences Inc. is set to report its financial results for Q4 and the full year of 2023 on March 26, 2024, along with a corporate update [1]. Group 1: Financial Reporting - The financial results will be disclosed after the market closes on March 26, 2024 [1]. - Analysts can participate in a Q&A session by pre-registering for the conference call [3]. Group 2: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The company has a pipeline of small molecule cancer therapeutics aimed at providing single-agent efficacy and enhancing the effectiveness of other anti-cancer therapies without overlapping toxicities [4]. - Two clinical-stage oral kinase inhibitors are under development: tuspetinib (HM43239) for relapsed or refractory acute myeloid leukemia (AML) and luxeptinib (CG-806) for relapsed or refractory hematologic malignancies [4].

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the "Public Offering") of 5,649,122 common shares of the Company (the "Common Shares") and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Com ...

Aptose Biosciences (NASDAQ:APTO) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company’s shares.Aptose Biosciences is selling 4,912,280 shares of its common stock at a price of $1.71 per share. That has it expecting gross proceeds of $8.4 million from the stock offering.To go along with this, each share of APTO stock sold in the offering comes with one warrant. These warrants are for the purchase of another share of the company’s stock. The ex ...

Core Viewpoint - Aptose Biosciences Inc. has announced a public offering of approximately 4.9 million common shares at a price of $1.71 per share, aiming to raise about $8.4 million before expenses [1][3] Group 1: Public Offering Details - The public offering consists of 4,912,280 common shares priced at $1.71 each, with warrants included for the same price [1] - Gross proceeds from the public offering are expected to be around $8.4 million, with underwriters having a 30-day option to purchase an additional 736,842 shares and/or warrants [1][3] - The public offering is anticipated to close on or about January 30, 2024, pending customary closing conditions [3] Group 2: Private Placement Details - A concurrent private placement of $4 million with Hanmi Pharmaceutical will occur, with Hanmi acquiring 19.97% of Aptose's outstanding shares post-placement at a price of $1.90 per share, an 11% premium over the public offering price [2] - Hanmi will also receive warrants to purchase common shares at $1.71 per share [2] - The private placement is expected to close on or about January 31, 2024, subject to customary closing conditions [3] Group 3: Use of Proceeds - The net proceeds from both the public offering and private placement will be utilized to support clinical trials for tuspetinib, manufacture clinical supplies, and for working capital and general corporate purposes [3] Group 4: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [7] - The lead product, tuspetinib, is being studied as a treatment for relapsed or refractory acute myeloid leukemia (AML) [7]

Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Operator Good afternoon. My name is Hope, and I will be your conference operator today. I would like to welcome everyone to t ...

Financial Performance - The net loss for the nine months ended September 30, 2023, was $39,252,000, compared to a net loss of $31,823,000 for the same period in 2022, indicating a 23.2% increase in losses[20]. - For the three months ended September 30, 2023, the net loss was $11.447 million compared to a net loss of $9.777 million for the same period in 2022, representing a 16.9% increase in losses[27]. - The company reported total comprehensive loss of $39,249,000 for the nine months ended September 30, 2023, compared to $31,840,000 for the same period in 2022[20]. - The net loss for the three months ended September 30, 2023, was $11,447,000, compared to a net loss of $9,777,000 for the same period in 2022, reflecting an increase in losses of 17%[20]. - The company recorded a loss per share of $6.14 for the nine months ended September 30, 2023, compared to a loss per share of $5.17 for the same period in 2022[75]. Assets and Liabilities - Total assets decreased from $51,027,000 as of December 31, 2022, to $20,876,000 as of September 30, 2023, representing a decline of approximately 59%[12][14]. - Total liabilities remained relatively stable, decreasing slightly from $13,286,000 to $13,100,000[15]. - Total shareholders' equity decreased significantly from $37,741,000 as of December 31, 2022, to $7,776,000 as of September 30, 2023, a decline of approximately 79.4%[17]. - The company’s working capital as of September 30, 2023, was approximately $7.3 million, down from $37.2 million as of December 31, 2022[36]. - Cash and cash equivalents dropped from $36,970,000 to $15,720,000, a decrease of about 57.6%[12]. Cash Flow and Financing - Cash used in operating activities for the nine months ended September 30, 2023, was $35.331 million, up from $23.671 million in the same period of 2022, indicating a 49.4% increase in cash outflow[27]. - The company plans to raise additional funds through equity financing under the 2022 ATM Facility, 2023 Committed Equity Facility, and the Hanmi Subscription Agreement to support operations[36]. - The company expects to continue experiencing negative cash flow from operations until regulatory approval is received for its product candidates[34]. - The company is evaluating strategies to obtain additional funding, including equity financing and restructuring operations to decrease expenses[40]. - The company’s current cash and cash equivalents are projected to support operations through March 2024, raising substantial doubt about its ability to continue as a going concern[33]. Research and Development - Research and development expenses for the three months ended September 30, 2023, were $8,256,000, up 25.5% from $6,578,000 for the same period in 2022[20]. - The company recognized $3.1 million in expenses related to the supply agreement with Hanmi for the nine months ended September 30, 2023[64]. - Supply costs paid to Hanmi amounted to $4.5 million for the nine months ended September 30, 2023, compared to nil in the same period of 2022[65]. - The company has two clinical-stage investigational products for hematological malignancies: tuspetinib and luxeptinib[32]. Shareholder Equity and Stock Options - The company issued 668,000 common shares under the Hanmi Subscription Agreement, raising $3,000,000[23]. - The weighted average number of common shares outstanding increased from 6,153,000 in Q3 2022 to 6,495,000 in Q3 2023[20]. - The Company granted 217 stock options during the nine months ended September 30, 2023, with a weighted average exercise price of $9.87[90]. - The Company issued a total of 328,438 Common Shares to Keystone at an average price of $3.5 per share, raising cash proceeds of $1.15 million as of September 30, 2023[70]. - The Company raised a total of $1.94 million in cash proceeds from issuing Common Shares under the 2022 ATM Facility as of September 30, 2023[72].

Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice - Chairman, President and Chief Executive Officer Rafael Bejar - Senior Vice President and Chief Medical Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Matthew Biegler - Oppenheimer Li Watsek - Cantor Fitzgerald Soumit Roy ...

Financial Performance - The net loss for the three months ended June 30, 2023, was $14,129 thousand, compared to a net loss of $10,565 thousand for the same period in 2022, indicating a 34% increase in losses [19]. - The net loss for the six months ended June 30, 2023, was $27.81 million, compared to a net loss of $22.05 million for the same period in 2022, indicating a 26% increase in losses [19]. - Basic and diluted loss per common share for the three months ended June 30, 2023, was $2.27, compared to $1.72 for the same period in 2022, reflecting a 32% increase in loss per share [19]. - The company reported a net loss per share of $4.47 for the six months ended June 30, 2023, compared to $3.59 for the same period in 2022, indicating a worsening loss per share [62]. - The company reported total operating expenses of $14,452 thousand for the three months ended June 30, 2023, which is a 35% increase from $10,673 thousand in the same period of 2022 [19]. Assets and Liabilities - Total assets decreased from $51,027 thousand as of December 31, 2022, to $26,575 thousand as of June 30, 2023, representing a decline of approximately 48% [16]. - Total current assets decreased from $49.52 million as of December 31, 2022, to $25.26 million as of June 30, 2023, a decline of 49% [15]. - Total liabilities decreased slightly from $13,286 thousand as of December 31, 2022, to $12,789 thousand as of June 30, 2023, a reduction of approximately 4% [16]. - Shareholders' equity fell from $37,741 thousand to $13,786 thousand, a decline of about 64% [16]. - Cash and cash equivalents dropped significantly from $36,970 thousand to $8,400 thousand, a decrease of about 77% [15]. Cash Flow and Funding - The company used $13.5 million in operating activities during the three months ended June 30, 2023, compared to $7.0 million in the same period in 2022 [25]. - The company utilized $24.8 million in cash for operating activities during the six months ended June 30, 2023, compared to $16.7 million for the same period in 2022 [25]. - The company plans to raise additional funds to support its operations, but there is no assurance that such funds will be available on acceptable terms [29]. - The company is evaluating strategies to obtain additional funding for future operations due to substantial doubt about its ability to continue as a going concern [36]. - The company has entered into a committed equity facility with Keystone Capital Partners, allowing for the sale of up to $25.0 million of common shares over a 24-month term [58]. Research and Development - Research and development expenses for the three months ended June 30, 2023, were $10,582 thousand, up 44% from $7,341 thousand in the same period of 2022 [19]. - The company has two clinical-stage investigational products for hematological malignancies: tuspetinib and luxeptinib [28]. - The company expects negative cash flow to continue until regulatory approval is received for its products or revenue exceeds expenses [30]. Stock and Equity - The company issued common shares under the 2022 ATM Facility, raising $1.1 million during the three months ended June 30, 2023 [25]. - A reverse stock split at a ratio of 1-for-15 was approved and took effect on June 6, 2023 [33]. - The company granted 215,000 stock options during the six months ended June 30, 2023, with a weighted average exercise price of $9.93 [68]. - The company recorded share-based payment expense of $2,643,000 for the six months ended June 30, 2023, down from $3,293,000 in the same period of 2022, reflecting a 20% decrease [79]. - The company has a maximum of 113,333 common shares available for sale under the Employee Stock Purchase Plan (ESPP) [67]. Accumulated Deficit - As of June 30, 2023, the company reported an accumulated deficit of approximately $492.1 million, up from $464.3 million as of December 31, 2022 [32]. - The company had working capital of approximately $13.3 million as of June 30, 2023, down from $37.2 million as of December 31, 2022 [32]. - Accrued liabilities increased to $8.084 million as of June 30, 2023, compared to $5.657 million on December 31, 2022 [51].